glucagon has been researched along with pasireotide in 12 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (pasireotide) | Trials (pasireotide) | Recent Studies (post-2010) (pasireotide) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 425 | 86 | 341 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Briner, U; Bruns, C; Lewis, I; Meno-Tetang, G; Weckbecker, G | 1 |
| Culler, MD; Janson, ET; Ludvigsen, E; Oberg, K; Sandler, S; Stridsberg, M; Taylor, JE | 1 |
| Atkinson, B; Bertherat, J; Biller, BM; Boscaro, M; Darby, CH; Findling, J; Freda, PU; Frohman, LA; Glusman, JE; Grossman, AB; Hu, K; Ludlam, WH; Melmed, S; Petersenn, S; Reincke, M; Snyder, P; Tabarin, A; Wang, Y | 1 |
| Bouillaud, E; Hu, K; Mann, K; Petersenn, S; Reséndiz, KH; Unger, N; Wang, Y; Weisshaar, B; Zhang, Y | 1 |
| Brueggen, J; Schmid, HA | 1 |
| Armstrong, D; Burke, P; Ciaraldi, TP; Henry, RR; Ligueros-Saylan, M; Mudaliar, S | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Chen, X; Darstein, C; Hu, K; Hu, P; Jiang, J; Lasher, J; Liu, H; Shen, G | 1 |
| Florio, T; Gatto, F | 1 |
| Higashihara, E; Horie, S; Kugita, M; Nagao, S; Nishii, K; Suzuki, A; Yamaguchi, T; Yuzawa, Y | 1 |
| Arnaldi, G; Barbot, M; Ceccato, F; Lizzul, L; Mondin, A; Plebani, M; Regazzo, D; Scaroni, C; Zaninotto, M; Zilio, M | 1 |
| Barbot, M; Basso, D; Ceccato, F; Giordano, C; Guarnotta, V; Mondin, A; Regazzo, D; Scaroni, C | 1 |
6 trial(s) available for glucagon and pasireotide
| Article | Year |
|---|---|
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Blood Glucose; Female; Glucagon; Humans; Hydrocortisone; Insulin; Male; Middle Aged; Oligopeptides; Pituitary ACTH Hypersecretion; Somatostatin | 2009 |
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Topics: Adult; Blood Glucose; Delayed-Action Preparations; Dose-Response Relationship, Drug; Glucagon; Humans; Infusions, Subcutaneous; Insulin; Male; Somatostatin; Young Adult | 2012 |
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
Topics: Adolescent; Adult; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Male; Middle Aged; Somatostatin | 2013 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Topics: Adult; Asian People; Blood Glucose; China; Cholesterol; Delayed-Action Preparations; Diarrhea; Dizziness; Dose-Response Relationship, Drug; Drug Administration Routes; Glucagon; Healthy Volunteers; Humans; Injections, Intramuscular; Injections, Subcutaneous; Insulin; Male; Nausea; Somatostatin; Triglycerides; Young Adult | 2014 |
Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Female; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Male; Middle Aged; Pilot Projects; Somatostatin | 2020 |
6 other study(ies) available for glucagon and pasireotide
| Article | Year |
|---|---|
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Topics: Animals; Binding, Competitive; Dose-Response Relationship, Drug; Glucagon; Human Growth Hormone; Humans; Insulin Antagonists; Insulin-Like Growth Factor I; Male; Protein Isoforms; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Somatostatin | 2002 |
Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues.
Topics: Animals; Dose-Response Relationship, Drug; Drug Interactions; Gastrointestinal Agents; Glucagon; Insulin; Insulin Secretion; Islets of Langerhans; Male; Octreotide; Rats; Rats, Sprague-Dawley; Somatostatin | 2007 |
Effects of somatostatin analogs on glucose homeostasis in rats.
Topics: Animals; Blood Glucose; Glucagon; Homeostasis; Hyperglycemia; Insulin; Insulin-Like Growth Factor I; Male; Octreotide; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Somatostatin | 2012 |
Does pasireotide directly modulate skeletal muscle metabolism?
Topics: Glucagon; Humans; Muscle, Skeletal; Somatostatin | 2017 |
Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
Topics: Animals; Blood Glucose; Body Weight; Cyclic AMP; Disease Models, Animal; Drug Interactions; Extracellular Signal-Regulated MAP Kinases; Glucagon; Heart; Humans; Hydrocortisone; Hyperglycemia; Insulin; Insulin-Like Growth Factor I; Ki-67 Antigen; Kidney; Liver; Male; Octreotide; Phosphoproteins; Polycystic Kidney, Autosomal Recessive; Rats; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases; Somatostatin | 2017 |
Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin Resistance; Meals; Pituitary ACTH Hypersecretion; Somatostatin | 2022 |